Antonia Digklia, MD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, shines a light on patients with pancreatic cancer who do not harbor a targetable mutation such as KRAS, and how next generation sequencing (NGS) can be utilized to potentially identify other targetable genes. Dr Digklia also comments on the use of immunotherapy for the treatment of patients with pancreatic cancer, while highlighting a currently ongoing phase I trial investigating the efficacy of dendritic cell vaccination in this patient population. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.